Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STERIMGLI: Durvalumab and hFSRT for Recurrent Glioblastoma
NCT02866747Phase 2Completed
- Sponsor
- Institut Claudius Regaud
- Start
- Jan 2017
- Primary completion
- Nov 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in glioblastoma (GBM), sponsored by Institut Claudius Regaud. Started Jan 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02866747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02866747.